Drug Trial Radar · NCT07161843
Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Dec 30, 2026
Study completion Feb 1, 2027
Sponsor
- Lead sponsor
- Ebima Clifford OkundayeIndustry
- Sponsor type
- Industry
- First posted
- Sep 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure
Conditions
- Acute Renal Failure (ARF)
- Acute Tubular Necrosis
Interventions
QRX-3Drug
Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of change in creatinine glomerular filtration rateTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neukidney Inc
Rosharon, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.